Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Tumor Biology
Erschienen in: Tumor Biology 7/2016

15.01.2016 | Original Article

Functional characterization of TRPM7 in nasopharyngeal carcinoma and its knockdown effects on tumorigenesis

verfasst von: Yi Qin, Zhi-Wei Liao, Jing-Yan Luo, Wen-Zhe Wu, An-Shang Lu, Pu-Xia Su, Bing-Quan Lai, Xiao-Xiao Wang

Erschienen in: Tumor Biology | Ausgabe 7/2016

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study was to evaluate the association of functional expression of TRPM7 with nasopharyngeal carcinoma (NPC) growth. We examined the correlation of TRPM7 expression with cell growth and proliferation, cell cycle, and apoptosis in vitro in NPC cell lines and NPC tumorigenesis in mice by conducting experiments in mice and by further analyzing the tumor volume and growth. We further explored to see whether there is any positive correlation with the TRPM7 knockdown in NPC cells with their sensitivity to radiation. We found that the functional expression of TRPM7 in nasopharyngeal carcinoma is a critical requirement for physiological processes such as cell cycle, resistance to apoptosis, and cell proliferation. TRPM7 knockdown also enhanced sensitivity to radiotherapy of nasopharyngeal carcinoma. Moreover, we identified TRPM7 as a novel potential regulator of cell proliferation in NPC, through signal transducer and activator of transcription 3 (STAT3)-mediated signaling pathway and other anti-apoptotic factors. TRPM7 and STAT3 activation might be critical for the growth of NPC cells and could be an effective target for treatment of nasopharyngeal carcinoma.
Literatur
1.
2.
Fang W, Li X, Jiang Q, Liu Z, Yang H, Wang S, et al. Transcriptional patterns, biomarkers and pathways characterizing nasopharyngeal carcinoma of southern China. J Transl Med. 2008;6:32.CrossRefPubMedPubMedCentral
3.
Chang ET, Adami HO. The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev. 2006;15:1765–77.CrossRefPubMed
4.
Sham JS, Choy D. Prognostic factors of nasopharyngeal carcinoma: a review of 759 patients. Br J Radiol. 1990;63:51–8.CrossRefPubMed
5.
Altun M, Fandi A, Dupuis O, Cvitkovic E, Krajina Z, Eschwege F. Undifferentiated nasopharyngeal cancer (UCNT): current diagnostic and therapeutic aspects. Int J Radiat Oncol Biol Phys. 1995;32:859–77.CrossRefPubMed
6.
Chow E, Payne D, Keane T, Panzarella T, Izard MA. Enhanced control by radiotherapy of cervical lymph node metastases arising from nasopharyngeal carcinoma compared with nodal metastases from other head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys. 1997;39:149–54.CrossRefPubMed
7.
Liu DB, Hu GY, Long GX, Qiu H, Mei Q, Hu GQ. Celecoxib induces apoptosis and cell-cycle arrest in nasopharyngeal carcinoma cell lines via inhibition of stat3 phosphorylation. Acta Pharmacol Sin. 2012;33:682–90.CrossRefPubMedPubMedCentral
8.
Yip KW, Mocanu JD, Au PY, Sleep GT, Huang D, Busson P, et al. Combination bcl-2 antisense and radiation therapy for nasopharyngeal cancer. Clin Cancer Res. 2005;11:8131–44.CrossRefPubMed
9.
Chen JP, Luan Y, You CX, Chen XH, Luo RC, Li R. TRPM7 regulates the migration of human nasopharyngeal carcinoma cell by mediating Ca(2+) influx. Cell Calcium. 2010;47:425–32.CrossRefPubMed
10.
Chen JP, Wang J, Luan Y, Wang CX, Li WH, Zhang JB, et al. Trpm7 promotes the metastatic process in human nasopharyngeal carcinoma. Cancer Lett. 2015;356:483–90.CrossRefPubMed
11.
Ma J, Liu L, Tang L, Zong J, Lin A, Lu T, et al. Retropharyngeal lymph node metastasis in nasopharyngeal carcinoma: prognostic value and staging categories. Clin Cancer Res. 2007;13:1445–52.CrossRefPubMed
12.
Tang L, Mao Y, Liu L, Liang S, Chen Y, Sun Y, et al. The volume to be irradiated during selective neck irradiation in nasopharyngeal carcinoma: analysis of the spread patterns in lymph nodes by magnetic resonance imaging. Cancer. 2009;115:680–8.CrossRefPubMed
13.
Sham JS, Choy D, Wei WI. Nasopharyngeal carcinoma: orderly neck node spread. Int J Radiat Oncol Biol Phys. 1990;19:929–33.CrossRefPubMed
14.
Ma BB, Chan AT. Systemic treatment strategies and therapeutic monitoring for advanced nasopharyngeal carcinoma. Expert Rev Anticancer Ther. 2006;6:383–94.CrossRefPubMed
15.
Mareel M, Leroy A. Clinical, cellular, and molecular aspects of cancer invasion. Physiol Rev. 2003;83:337–76.CrossRefPubMed
16.
Entschladen F, Zanker KS. Locomotion of tumor cells: a molecular comparison to migrating pre- and postmitotic leukocytes. J Cancer Res Clin Oncol. 2000;126:671–81.CrossRefPubMed
17.
Monteith GR, McAndrew D, Faddy HM, Roberts-Thomson SJ. Calcium and cancer: targeting ca2+ transport. Nat Rev Cancer. 2007;7:519–30.CrossRefPubMed
18.
Jiang J, Li MH, Inoue K, Chu XP, Seeds J, Xiong ZG. Transient receptor potential melastatin 7-like current in human head and neck carcinoma cells: role in cell proliferation. Cancer Res. 2007;67:10929–38.CrossRefPubMedPubMedCentral
19.
Guilbert A, Gautier M, Dhennin-Duthille I, Haren N, Sevestre H, Ouadid-Ahidouch H. Evidence that trpm7 is required for breast cancer cell proliferation. Am J Physiol Cell Physiol. 2009;297:C493–502.CrossRefPubMed
20.
Kim BJ, Park EJ, Lee JH, Jeon JH, Kim SJ, So I. Suppression of transient receptor potential melastatin 7 channel induces cell death in gastric cancer. Cancer Sci. 2008;99:2502–9.CrossRefPubMed
21.
Kim BJ, Nah SY, Jeon JH, So I, Kim SJ. Transient receptor potential melastatin 7 channels are involved in ginsenoside rg3-induced apoptosis in gastric cancer cells. Basic Clin Pharmacol Toxicol. 2011;109:233–9.CrossRefPubMed
22.
Jiang J, Lei WB, Shi JB, Su ZZ, Xiong ZG. Transient receptor potential melastatin 7 channel protein in human head and neck carcinoma cells and role in cell proliferation. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2008;43:451–5.PubMed
23.
Yee NS, Zhou W, Liang IC. Transient receptor potential ion channel Trpm7 regulates exocrine pancreatic epithelial proliferation by Mg2+-sensitive Socs3a signaling in development and cancer. Dis Model Mech. 2011;4:240–54.CrossRefPubMedPubMedCentral
24.
Rybarczyk P, Gautier M, Hague F, Dhennin-Duthille I, Chatelain D, Kerr-Conte J, et al. Transient receptor potential melastatin-related 7 channel is overexpressed in human pancreatic ductal adenocarcinomas and regulates human pancreatic cancer cell migration. Int J Cancer. 2012;131:E851–61.CrossRefPubMed
25.
Sun Y, Selvaraj S, Varma A, Derry S, Sahmoun AE, Singh BB. Increase in serum Ca2+/Mg2+ ratio promotes proliferation of prostate cancer cells by activating TRPM7 channels. J Biol Chem. 2013;288:255–63.CrossRefPubMed
26.
Hanano T, Hara Y, Shi J, Morita H, Umebayashi C, Mori E, et al. Involvement of Trpm7 in cell growth as a spontaneously activated Ca2+ entry pathway in human retinoblastoma cells. J Pharmacol Sci. 2004;95:403–19.CrossRefPubMed
27.
Zierler S, Yao G, Zhang Z, Kuo WC, Porzgen P, Penner R, et al. Waixenicin a inhibits cell proliferation through magnesium-dependent block of transient receptor potential melastatin 7 (trpm7) channels. J Biol Chem. 2011;286:39328–35.CrossRefPubMedPubMedCentral
28.
Sahni J, Tamura R, Sweet IR, Scharenberg AM. Trpm7 regulates quiescent/proliferative metabolic transitions in lymphocytes. Cell Cycle. 2010;9:3565–74.CrossRefPubMedPubMedCentral
29.
Liu M, Inoue K, Leng T, Guo S, Xiong ZG. Trpm7 channels regulate glioma stem cell through stat3 and notch signaling pathways. Cell Signal. 2014;26:2773–81.CrossRefPubMedPubMedCentral
30.
Zhou W, Guo S, Xiong Z, Liu M. Oncogenic role and therapeutic target of transient receptor potential melastatin 7 channel in malignancy. Expert Opin Ther Targets. 2014;18:1177–96.CrossRefPubMed
31.
Nadler MJ, Hermosura MC, Inabe K, Perraud AL, Zhu Q, Stokes AJ, et al. Ltrpc7 is a mg.atp-regulated divalent cation channel required for cell viability. Nature. 2001;411:590–5.CrossRefPubMed
32.
Runnels LW, Yue L, Clapham DE. Trp-plik, a bifunctional protein with kinase and ion channel activities. Science. 2001;291:1043–7.CrossRefPubMed
33.
Jiang X, Newell EW, Schlichter LC. Regulation of a trpm7-like current in rat brain microglia. J Biol Chem. 2003;278:42867–76.CrossRefPubMed
34.
Schmitz C, Perraud AL, Johnson CO, Inabe K, Smith MK, Penner R, et al. Regulation of vertebrate cellular Mg2+ homeostasis by Trpm7. Cell. 2003;114:191–200.CrossRefPubMed
35.
Wykes RC, Lee M, Duffy SM, Yang W, Seward EP, Bradding P. Functional transient receptor potential melastatin 7 channels are critical for human mast cell survival. J Immunol. 2007;179:4045–52.CrossRefPubMed
36.
Lui VW, Wong EY, Ho Y, Hong B, Wong SC, Tao Q, et al. Stat3 activation contributes directly to Epstein-Barr virus-mediated invasiveness of nasopharyngeal cancer cells in vitro. Int J Cancer. 2009;125:1884–93.CrossRefPubMed
37.
Wang Z, Luo F, Li L, Yang L, Hu D, Ma X, et al. Stat3 activation induced by Epstein-Barr virus latent membrane protein 1 causes vascular endothelial growth factor expression and cellular invasiveness via jak3 and erk signaling. Eur J Cancer. 2010;46:2996–3006.CrossRefPubMed
38.
Ma N, Kawanishi M, Hiraku Y, Murata M, Huang GW, Huang Y, et al. Reactive nitrogen species-dependent dna damage in ebv-associated nasopharyngeal carcinoma: the relation to stat3 activation and egfr expression. Int J Cancer. 2008;122:2517–25.CrossRefPubMed
39.
Liu YP, Tan YN, Wang ZL, Zeng L, Lu ZX, Li LL, et al. Phosphorylation and nuclear translocation of stat3 regulated by the Epstein-Barr virus latent membrane protein 1 in nasopharyngeal carcinoma. Int J Mol Med. 2008;21:153–62.PubMed
40.
Peng G, Cao RB, Li YH, Zou ZW, Huang J, Ding Q. Alterations of cell cycle control proteins shp1/2, p16, cdk4 and cyclin d1 in radioresistant nasopharyngeal carcinoma cells. Mol Med Rep. 2014;10:1709–16.PubMedPubMedCentral
41.
Fu SM, Xu MX, Lin SM, Liang Z, Cai JH. Association of cyclin d1 and survivin expression with sensitivity to radiotherapy in patients with nasopharyngeal carcinoma. Genet Mol Res. 2014;13:3502–9.CrossRefPubMed
42.
Pan Y, Zhang Q, Tian L, Wang X, Fan X, Zhang H, et al. Jab1/csn5 negatively regulates p27 and plays a role in the pathogenesis of nasopharyngeal carcinoma. Cancer Res. 2012;72:1890–900.CrossRefPubMedPubMedCentral
43.
Yee NS, Zhou W, Lee M. Transient receptor potential channel trpm8 is over-expressed and required for cellular proliferation in pancreatic adenocarcinoma. Cancer Lett. 2010;297:49–55.CrossRefPubMedPubMedCentral
44.
Chun SG, Zhou W, Yee NS. Combined targeting of histone deacetylases and hedgehog signaling enhances cytoxicity in pancreatic cancer. Cancer Biol Ther. 2009;8:1328–39.CrossRefPubMed
45.
Liu X, Lv XB, Wang XP, Sang Y, Xu S, Hu K, et al. Mir-138 suppressed nasopharyngeal carcinoma growth and tumorigenesis by targeting the ccnd1 oncogene. Cell Cycle. 2012;11:2495–506.CrossRefPubMed
46.
Meng X, Cai C, Wu J, Cai S, Ye C, Chen H, et al. Trpm7 mediates breast cancer cell migration and invasion through the mapk pathway. Cancer Lett. 2013;333:96–102.CrossRefPubMed
47.
Wang J, Xiao L, Luo CH, Zhou H, Hu J, Tang YX, et al. Overexpression of trpm7 is associated with poor prognosis in human ovarian carcinoma. Asian Pac J Cancer Prev. 2014;15:3955–8.CrossRefPubMed
48.
Dhennin-Duthille I, Gautier M, Faouzi M, Guilbert A, Brevet M, Vaudry D, et al. High expression of transient receptor potential channels in human breast cancer epithelial cells and tissues: correlation with pathological parameters. Cell Physiol Biochem. 2011;28:813–22.CrossRefPubMed
49.
Gao H, Chen X, Du X, Guan B, Liu Y, Zhang H. Egf enhances the migration of cancer cells by up-regulation of trpm7. Cell Calcium. 2011;50:559–68.CrossRefPubMed
50.
Middelbeek J, Kuipers AJ, Henneman L, Visser D, Eidhof I, van Horssen R, et al. Trpm7 is required for breast tumor cell metastasis. Cancer Res. 2012;72:4250–61.CrossRefPubMed
51.
Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature. 2001;411:342–8.CrossRefPubMed
52.
53.
Orr AW, Helmke BP, Blackman BR, Schwartz MA. Mechanisms of mechanotransduction. Dev Cell. 2006;10:11–20.CrossRefPubMed
54.
Chou J, Lin YC, Kim J, You L, Xu Z, He B, et al. Nasopharyngeal carcinoma—review of the molecular mechanisms of tumorigenesis. Head Neck. 2008;30:946–63.CrossRefPubMedPubMedCentral
55.
Davis FM, Azimi I, Faville RA, Peters AA, Jalink K, Putney JJ, et al. Induction of epithelial-mesenchymal transition (emt) in breast cancer cells is calcium signal dependent. Oncogene. 2014;33:2307–16.CrossRefPubMed
56.
Shi W, Bastianutto C, Li A, Perez-Ordonez B, Ng R, Chow KY, et al. Multiple dysregulated pathways in nasopharyngeal carcinoma revealed by gene expression profiling. Int J Cancer. 2006;119:2467–75.CrossRefPubMed
57.
Krikelis D, Bobos M, Karayannopoulou G, Resiga L, Chrysafi S, Samantas E, et al. Expression profiling of 21 biomolecules in locally advanced nasopharyngeal carcinomas of Caucasian patients. BMC Clin Pathol. 2013;13:1.CrossRefPubMedPubMedCentral
58.
Wu D, Chen L, Liao W, Ding Y, Zhang Q, Li Z, et al. Fascin1 expression predicts poor prognosis in patients with nasopharyngeal carcinoma and correlates with tumor invasion. Ann Oncol. 2010;21:589–96.CrossRefPubMed
59.
Segawa Y, Oda Y, Yamamoto H, Shiratsuchi H, Hirakawa N, Komune S, et al. Close correlation between cxcr4 and vegf expression and their prognostic implications in nasopharyngeal carcinoma. Oncol Rep. 2009;21:1197–202.PubMed
60.
Qian CN, Guo X, Cao B, Kort EJ, Lee CC, Chen J, et al. Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma. Cancer Res. 2002;62:589–96.PubMed
61.
Oudejans JJ, Harijadi H, Kummer JA, Tan IB, Bloemena E, Middeldorp JM, et al. High numbers of granzyme b/cd8-positive tumour-infiltrating lymphocytes in nasopharyngeal carcinoma biopsies predict rapid fatal outcome in patients treated with curative intent. J Pathol. 2002;198:468–75.CrossRefPubMed
62.
Real PJ, Sierra A, De Juan A, Segovia JC, Lopez-Vega JM, Fernandez-Luna JL. Resistance to chemotherapy via stat3-dependent overexpression of bcl-2 in metastatic breast cancer cells. Oncogene. 2002;21:7611–8.CrossRefPubMed
63.
Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S, et al. Regulation of the innate and adaptive immune responses by stat-3 signaling in tumor cells. Nat Med. 2004;10:48–54.CrossRefPubMed
64.
Chen H, Hutt-Fletcher L, Cao L, Hayward SD. A positive autoregulatory loop of lmp1 expression and stat activation in epithelial cells latently infected with Epstein-Barr virus. J Virol. 2003;77:4139–48.CrossRefPubMedPubMedCentral
65.
66.
Wang X, Crowe PJ, Goldstein D, Yang JL. Stat3 inhibition, a novel approach to enhancing targeted therapy in human cancers (review). Int J Oncol. 2012;41:1181–91.PubMed
67.
Yu H, Jove R. The stats of cancer—new molecular targets come of age. Nat Rev Cancer. 2004;4:97–105.CrossRefPubMed
68.
Frank DA. Stat3 as a central mediator of neoplastic cellular transformation. Cancer Lett. 2007;251:199–210.CrossRefPubMed
69.
Buettner R, Mora LB, Jove R. Activated stat signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res. 2002;8:945–54.PubMed
70.
Li H, Liu A, Zhao Z, Xu Y, Lin J, Jou D, et al. Fragment-based drug design and drug repositioning using multiple ligand simultaneous docking (mlsd): identifying celecoxib and template compounds as novel inhibitors of signal transducer and activator of transcription 3 (stat3). J Med Chem. 2011;54:5592–6.CrossRefPubMedPubMedCentral
71.
Liu Y, Liu A, Li H, Li C, Lin J. Celecoxib inhibits interleukin-6/interleukin-6 receptor-induced jak2/stat3 phosphorylation in human hepatocellular carcinoma cells. Cancer Prev Res (Phila). 2011;4:1296–305.CrossRef
72.
Reed S, Li H, Li C, Lin J. Celecoxib inhibits stat3 phosphorylation and suppresses cell migration and colony forming ability in rhabdomyosarcoma cells. Biochem Biophys Res Commun. 2011;407:450–5.CrossRefPubMed
Metadaten
Titel
Functional characterization of TRPM7 in nasopharyngeal carcinoma and its knockdown effects on tumorigenesis
verfasst von
Yi Qin
Zhi-Wei Liao
Jing-Yan Luo
Wen-Zhe Wu
An-Shang Lu
Pu-Xia Su
Bing-Quan Lai
Xiao-Xiao Wang
Publikationsdatum
15.01.2016
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 7/2016
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4636-z

Weitere Artikel der Ausgabe 7/2016

Tumor Biology 7/2016 Zur Ausgabe

Original Article

Genetic variations in interleukin-6 polymorphism and the association with susceptibility and overall survival of osteosarcoma

Original Article

Cancer stem cell markers in pediatric sarcomas: Sox2 is associated with tumorigenicity in immunodeficient mice

Original Article

Monitoring the treatment outcome in endometrial cancer patients by CEA and TATI

Original Article

Curcumin analogue, A13, exhibits anti-leukemia effect via inhibiting STAT3

Original Article

A novel variable exonic region and differential expression of LINC00663 non-coding RNA in various cancer cell lines and normal human tissue samples

Original Article

Evaluation of RIP1K and RIP3K expressions in the malignant and benign breast tumors

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise